Skip to main content
Back to Journal Club
Topical Treatment of AK in Organ Transplant Recipients - Feasibility Study (BJD)

Hasan ZU, Ahmed I, Matin RN, et al.
British Journal of Dermatology (2022)

Open AccessJC: October 2022

This feasibility study evaluated topical treatment of actinic keratoses (AKs) in organ transplant recipients, a population with a high burden of AKs and elevated risk of progression to SCC. The study demonstrated that topical field therapy is feasible and tolerable in transplant recipients, supporting its role in skin cancer prevention.

Take-Home Messages

  • •Topical field therapy for AKs is feasible and well-tolerated in organ transplant recipients despite their immunosuppressed state.
  • •Regular AK field treatment in transplant recipients may help reduce the high rate of progression to invasive SCC in this population.
PubMed →DOI →Full Text →

Topic

Transplant & Immunosuppression

Skin cancer in organ transplant recipients, immunosuppression management

Abstract

The risk of cutaneous squamous cell carcinoma (cSCC) is significantly increased in organ transplant recipients (OTRs). Clearance of actinic keratoses (AKs) is generally regarded as a surrogate biomarker for cSCC prevention. OTR-cSCC chemoprevention with topical AK treatments has not been investigated in randomized controlled trials (RCTs), although there is evidence that 5% 5-fluorouracil (5-FU) may be chemoprotective in immunocompetent patients. To assess the feasibility, activity and evalua...

View on PubMedDOIFree Full Text
Literature review only. This summary is an editorial interpretation and may not reflect the complete findings of the original publication. Always refer to the full-text article for clinical decision-making.